TAM
REGN icon

Telluride Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Telluride Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,009
Closed -$303K – 320
2014
Q1 		$303K Buy
+1,009
New +$311K 0.25% 130

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Telluride Asset Management's REGN Position: Q2 2014 in Review

Telluride Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 1,009 shares — an estimated $303K sold.

Telluride Asset Management first reported a position in REGN in Q1 2014 and held it in 1 quarter. The position peaked at $303K in Q1 2014. 448 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • Telluride Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Telluride Asset Management sold 1,009 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $303K.
  • Telluride Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Telluride Asset Management's Regeneron Pharmaceuticals position peaked at $303K in Q1 2014.
  • 448 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.